Exelixis Stock: Building On A Blockbuster (NASDAQ:EXEL)
danr13/iStock via Getty Images This is my first look at Exelixis (NASDAQ:EXEL). It is a young commercial stage biopharma that is enjoying success with its CABOMETYX (cabozantinib). In this article, I evaluate Exelixis’ investment merits […]
